Advances in non Castrate Sensitive Metastatic Prostate Cancer
Nicholas J. Vogelzang, MD, FASCO, FACP, on metastatic castration-resistant prostate cancer patients Understanding non metastatic castration resistant prostate cancer with Dr. Hamilton A discussion on the characteristics and differences among castration-sensitive, nonmetastatic castration-resistant, and metastatic Ravi Madan, MD, National Cancer Institute, Bethesda, MD, discusses the barriers to treatment intensification in metastatic Triplet therapy is abiraterone or darolutamide plus docetaxel and androgen deprivation therapy (ADT) in overall patient population. Triplet ...